Amgen Inc
NASDAQ:AMGN

Watchlist Manager
Amgen Inc Logo
Amgen Inc
NASDAQ:AMGN
Watchlist
Price: 263.38 USD 0.84% Market Closed
Market Cap: 141.6B USD
Have any thoughts about
Amgen Inc?
Write Note

Wall Street
Price Targets

AMGN Price Targets Summary
Amgen Inc

Wall Street analysts forecast AMGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AMGN is 336.33 USD with a low forecast of 196.95 USD and a high forecast of 425.25 USD.

Lowest
Price Target
196.95 USD
25% Downside
Average
Price Target
336.33 USD
28% Upside
Highest
Price Target
425.25 USD
61% Upside

AMGN Last Price Targets
Amgen Inc

The latest public price target was made on Nov 12, 2024 by Michael Yee from Jefferies , who expects AMGN stock to rise by 44% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Michael Yee
Jefferies
380 USD
Upside 44%
1 month ago
Nov 12, 2024
Jefferies on Amgen (AMGN): 'Thoughts on Phase I bone data for AMG-133 - seems non-issue'
StreetInsider
Olivia Brayer
Cantor Fitzgerald
405 USD
Upside 54%
1 month ago
Nov 12, 2024
Cantor Fitzgerald Locates Data on Amgen (AMGN) Hidden in Tables for MariTide's Data
StreetInsider
Terence Flynn
Morgan Stanley
319 USD
Upside 21%
2 months ago
Oct 21, 2024
Morgan Stanley names Amgen 'catalyst-driven idea' into Phase 2 MariTide data
TheFly
Salveen Richter
Goldman Sachs
369 USD
Upside 40%
2 months ago
Oct 16, 2024
Goldman Sachs Reiterates Conviction Buy Rating on Amgen (AMGN)
StreetInsider
Carter Gould
Barclays
315 USD
Upside 20%
2 months ago
Oct 7, 2024
Amgen price target raised to $315 from $300 at Barclays
TheFly
Evan David Seigerman
BMO Capital
362 USD
Upside 37%
2 months ago
Sep 25, 2024
BMO Capital Reiterates Outperform Rating on Amgen (AMGN)
StreetInsider
Brian Skorney
Robert W. Baird
215 USD
Downside 18%
2 months ago
Sep 25, 2024
Baird Reiterates Underperform Rating on Amgen (AMGN)
StreetInsider
Christopher Raymond
Raymond James
344 USD
Upside 31%
2 months ago
Sep 25, 2024
Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)
StreetInsider
Mohit Bansal
Wells Fargo
335 USD
Upside 27%
4 months ago
Aug 7, 2024
Amgen downgraded to Equal Weight from Overweight at Wells Fargo
TheFly
Terence Flynn
Morgan Stanley
303 USD
Upside 15%
4 months ago
Aug 6, 2024
Amgen Gears Up For Q2 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Benzinga
Gregory Renza
RBC Capital
332 USD
Upside 26%
6 months ago
Jun 14, 2024
Amgen (AMGN) PT Raised to $332 at RBC Capital
StreetInsider
Jay Olson
Oppenheimer
380 USD
Upside 44%
7 months ago
May 17, 2024
Oppenheimer Reiterates Outperform Rating on Amgen (AMGN)
StreetInsider
Salim Syed
Mizuho Securities
235 USD
Downside 11%
7 months ago
May 9, 2024
Amgen (AMGN) PT Raised to $235 at Mizuho
StreetInsider
Terence Flynn
Morgan Stanley
310 USD
Upside 18%
7 months ago
May 3, 2024
Amgen price target raised to $310 from $271 at Morgan Stanley
TheFly
Evan David Seigerman
BMO Capital
355 USD
Upside 35%
7 months ago
May 3, 2024
Amgen (AMGN) PT Raised to $355 at BMO Capital
StreetInsider
Carter Gould
Barclays
300 USD
Upside 14%
7 months ago
May 3, 2024
Barclays Upgrades Amgen (AMGN) to Equalweight
StreetInsider
Colin Bristow
UBS
307 USD
Upside 17%
7 months ago
May 3, 2024
Amgen (AMGN) PT Raised to $307 at UBS
StreetInsider
Mohit Bansal
Wells Fargo
320 USD
Upside 21%
8 months ago
Apr 17, 2024
Wells Fargo Reiterates Overweight Rating on Amgen (AMGN)
StreetInsider
Jay Olson
Oppenheimer
280 USD
Upside 6%
1 year ago
Sep 13, 2023
These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
Benzinga
Michael Yee
Jefferies
310 USD
Upside 18%
1 year ago
Sep 13, 2023
These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
Benzinga
Mohit Bansal
Wells Fargo
265 USD
Upside 1%
1 year ago
Apr 12, 2023
These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
Benzinga
Mohit Bansal
Wells Fargo
275 USD
Upside 4%
1 year ago
Mar 10, 2023
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga
Unknown Analyst
Leerink Partners
267 USD
Upside 1%
1 year ago
Feb 2, 2023
SVB Leerink Maintains Market Perform on Amgen, Lowers Price Target to $267
Benzinga
Unknown Analyst
BMO Capital
253 USD
Downside 4%
1 year ago
Feb 1, 2023
BMO Capital Maintains Market Perform on Amgen, Lowers Price Target to $253
Benzinga
Unknown Analyst
Oppenheimer
294 USD
Upside 12%
1 year ago
Feb 1, 2023
Oppenheimer Maintains Outperform on Amgen, Lowers Price Target to $294
Benzinga
Unknown Analyst
Cowen & Co.
289 USD
Upside 10%
1 year ago
Feb 1, 2023
Cowen & Co. Maintains Outperform on Amgen, Lowers Price Target to $289
Benzinga
Unknown Analyst
RBC Capital
258 USD
Downside 2%
1 year ago
Feb 1, 2023
RBC Capital Maintains Sector Perform on Amgen, Lowers Price Target to $258
Benzinga
Show More Price Targets
Show Less Price Targets
Michael Yee
Jefferies
Price Target 380 USD
Upside/Downside 44%
View Source
Olivia Brayer
Cantor Fitzgerald
Price Target 405 USD
Upside/Downside 54%
View Source
Terence Flynn
Morgan Stanley
Price Target 319 USD
Upside/Downside 21%
View Source
Salveen Richter
Goldman Sachs
Price Target 369 USD
Upside/Downside 40%
View Source
Carter Gould
Barclays
Price Target 315 USD
Upside/Downside 20%
View Source
Evan David Seigerman
BMO Capital
Price Target 362 USD
Upside/Downside 37%
View Source
Brian Skorney
Robert W. Baird
Price Target 215 USD
Upside/Downside 18%
View Source
Christopher Raymond
Raymond James
Price Target 344 USD
Upside/Downside 31%
View Source
Mohit Bansal
Wells Fargo
Price Target 335 USD
Upside/Downside 27%
View Source
Terence Flynn
Morgan Stanley
Price Target 303 USD
Upside/Downside 15%
View Source
Gregory Renza
RBC Capital
Price Target 332 USD
Upside/Downside 26%
View Source
Jay Olson
Oppenheimer
Price Target 380 USD
Upside/Downside 44%
View Source
Salim Syed
Mizuho Securities
Price Target 235 USD
Upside/Downside 11%
View Source
Terence Flynn
Morgan Stanley
Price Target 310 USD
Upside/Downside 18%
View Source
Evan David Seigerman
BMO Capital
Price Target 355 USD
Upside/Downside 35%
View Source
Carter Gould
Barclays
Price Target 300 USD
Upside/Downside 14%
View Source
Colin Bristow
UBS
Price Target 307 USD
Upside/Downside 17%
View Source
Mohit Bansal
Wells Fargo
Price Target 320 USD
Upside/Downside 21%
View Source
Jay Olson
Oppenheimer
Price Target 280 USD
Upside/Downside 6%
View Source
Michael Yee
Jefferies
Price Target 310 USD
Upside/Downside 18%
View Source
Mohit Bansal
Wells Fargo
Price Target 265 USD
Upside/Downside 1%
View Source
Mohit Bansal
Wells Fargo
Price Target 275 USD
Upside/Downside 4%
View Source
Unknown Analyst
Leerink Partners
Price Target 267 USD
Upside/Downside 1%
View Source
Unknown Analyst
BMO Capital
Price Target 253 USD
Upside/Downside 4%
View Source
Unknown Analyst
Oppenheimer
Price Target 294 USD
Upside/Downside 12%
View Source
Unknown Analyst
Cowen & Co.
Price Target 289 USD
Upside/Downside 10%
View Source
Unknown Analyst
RBC Capital
Price Target 258 USD
Upside/Downside 2%
View Source
Show More Price Targets
Show Less Price Targets
Amgen Inc Competitors:
Price Targets
KRON
Kronos Bio Inc
73% Upside
688105
Nanjing Vazyme Biotech Co Ltd
6% Upside
KNSA
Kiniksa Pharmaceuticals Ltd
78% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
33% Upside
MAAT
Maat Pharma SA
105% Upside
FYB
Formycon AG
80% Upside
300294
China Resources Boya Bio pharmaceutical Group Co Ltd
17% Upside
OCGN
Ocugen Inc
625% Upside

Revenue
Forecast

Revenue Estimate
Amgen Inc

For the last 8 years the compound annual growth rate for Amgen Inc's revenue is 3%. The projected CAGR for the next 4 years is 7%.

3%
Past Growth
7%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Amgen Inc

For the last 8 years the compound annual growth rate for Amgen Inc's operating income is -1%. The projected CAGR for the next 4 years is 19%.

-1%
Past Growth
19%
Estimated Growth
Estimates Accuracy
-15%
Average Miss

Net Income
Forecast

Net Income Estimate
Amgen Inc

For the last 8 years the compound annual growth rate for Amgen Inc's net income is 0%. The projected CAGR for the next 4 years is 16%.

0%
Past Growth
16%
Estimated Growth
Estimates Accuracy
-18%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AMGN's stock price target?
Price Target
336.33 USD

According to Wall Street analysts, the average 1-year price target for AMGN is 336.33 USD with a low forecast of 196.95 USD and a high forecast of 425.25 USD.

What is Amgen Inc's Revenue forecast?
Projected CAGR
7%

For the last 8 years the compound annual growth rate for Amgen Inc's revenue is 3%. The projected CAGR for the next 4 years is 7%.

What is Amgen Inc's Operating Income forecast?
Projected CAGR
19%

For the last 8 years the compound annual growth rate for Amgen Inc's operating income is -1%. The projected CAGR for the next 4 years is 19%.

What is Amgen Inc's Net Income forecast?
Projected CAGR
16%

For the last 8 years the compound annual growth rate for Amgen Inc's net income is 0%. The projected CAGR for the next 4 years is 16%.

Back to Top